Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Blow Tests FDA’s, Industry’s Patience For Illicit Drug-Related Product Brands

This article was originally published in The Tan Sheet

Executive Summary

Three months after FDA acted on a trade group's complaint and took enforcement action against an energy beverage firm for marketing its product as an alternative to an illicit street drug, the dietary supplement industry has another opportunity to judge how well the agency responds to a firm using drug jargon to market a product

You may also be interested in...



FDA Says No To Street Drug Alternatives Posing As Supplements

The agency warns Arco Globus Trading LLC to immediately stop marketing purported dietary supplements that it promotes as alternatives to illicit street drugs, including one with an active pharmaceutical antihistamine. The firm's Legal Lean Syrup and Coco Loko are unapproved and misbranded new drugs, the agency says.

Herbal Sleep Aid With Rx 'Reformulation' Gives FDA A Nightmare

FDA inspects Belmora's website and product labeling in March and issues a warning letter that firm’s Elavil OTC Sleep Aid is an unapproved new drug with inadequate directions for its intended use.

Hi-Tech 'OTC Diet Aid' Could Run Regulatory Risk With Ionamin Brand

The firm launches Ionamin as its second weight loss supplement using a brand name once used for a drug as it contests FTC allegations of failing to comply with a settlement not to make unsubstantiated claims.

Related Content

Topics

UsernamePublicRestriction

Register

PS100768

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel